CD274 and squamous cell carcinoma: KEYNOTE-590 demonstrated a marked survival advantage for pembrolizumab plus chemotherapy in advanced esophageal and GEJ adenocarcinoma or squamous cell carcinoma with PD-L1 CPS ≥ 10 (13.5 vs. 9.4 months; HR 0.62) [59].